Volume

Advances in preclinical evaluation of experimental antibody-drug conjugates

Tackling cisplatin resistance in ovarian cancer: what can we do?

Targeting DNA topoisomerases: past & future

Experimental models of endocrine responsive breast cancer: strengths, limitations, and use

The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors

Notch signaling in female cancers: a multifaceted node to overcome drug resistance

Targeting DNA repair pathways to overcome cancer drug resistance

MYC inhibitors in multiple myeloma

The aqueous extract of brucea javanica reduces tumorigenicity of human lung cancer tumorspheres

Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer

Recent advances in tumor-targeting chemotherapy drugs

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat

Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate

SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma

Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review

Barriers to achieving a cure in lymphoma

Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance

Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxel

Gene expression profiling as a prognostic tool in multiple myeloma

EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF<sup>V600E</sup> mutation: a case report and review of literature

Overcoming drug resistance by targeting protein homeostasis in multiple myeloma

Shenmai injection enhances cisplatin-induced apoptosis through regulation of Mfn2-dependent mitochondrial dynamics in lung adenocarcinoma A549/DDP cells

Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/